Unit of Infectious Diseases, Microbiology and Preventive Medicine, Instituto de Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain.
J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):446-9. doi: 10.1097/QAI.0b013e3182364513.
Optimizing treatment for patients with persistent low-level viremia is complicated because most genotyping tests are validated for viral loads >1000 copies per milliliter. In this study, genotypes of 92 treatment-experienced patients with persistent low-level viremia were determined using an in-house assay. Based on the resistance profiles obtained from genotyping and patient pharmacologic history, patients were either maintained on their antiviral regimen (n = 51) or received an optimized regimen (n = 41). In the group receiving optimized treatment, undetectable viral loads were achieved in 73.2% at 6 months and at 90.2% at 1 year, indicating that treatment guided by genotyping of patients with low-level viremia is effective in achieving viral suppression.
优化持续性低水平病毒血症患者的治疗方案较为复杂，因为大多数基因分型检测都针对病毒载量>1000 拷贝/毫升进行了验证。本研究采用内部检测方法对 92 例持续性低水平病毒血症的治疗经验丰富的患者进行了基因分型。根据基因分型和患者药物治疗史获得的耐药谱，患者要么维持其抗病毒方案（n=51），要么接受优化方案（n=41）。在接受优化治疗的组中，6 个月时 73.2%的患者病毒载量不可检测，1 年时 90.2%的患者病毒载量不可检测，这表明根据低水平病毒血症患者的基因分型指导治疗可有效实现病毒抑制。
